

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 786 256 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

30.07.1997 Bulletin 1997/31

(51) Int Cl.: A61K 38/22

(21) Application number: 97300301.5

(22) Date of filing: 17.01.1997

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

Designated Extension States:

AL LT LV RO SI

(30) Priority: 19.01.1996 US 10244

07.02.1996 GB 9602466

(71) Applicant: ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)

(72) Inventors:

• Beals, John Michael
Indianapolis, Indiana 46278-1853 (US)

- Dodd, Steven Witt
Indianapolis, Indiana 46254 (US)
- Milligan, Rohn Lee, Jr.
Indianapolis, Indiana 46254 (US)
- Pekar, Allen Howard
Indianapolis, Indiana 46220 (US)

(74) Representative: Hudson, Christopher Mark et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) Obesity protein formulations

(57) The present invention discloses a soluble parenteral formulation, comprising an obesity protein analog and a preservative, said formulation having a low

ionic strength. The low ionic strength allows the preparation of a commercially viable multi-use pharmaceutical product.

BEST AVAILABLE COPY